Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 347,394
  • Shares Outstanding, K 50,129
  • Annual Sales, $ 500 K
  • Annual Income, $ -85,020 K
  • 60-Month Beta 1.40
  • Price/Sales 8.09
  • Price/Cash Flow N/A
  • Price/Book 1.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.08
  • Low Estimate -0.76
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +59.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +12.48%
on 01/14/20
11.25 -39.91%
on 12/26/19
-4.32 (-38.99%)
since 12/24/19
3-Month
6.01 +12.48%
on 01/14/20
11.38 -40.62%
on 12/24/19
-2.85 (-29.66%)
since 10/24/19
52-Week
6.01 +12.48%
on 01/14/20
18.22 -62.90%
on 08/08/19
-3.46 (-33.86%)
since 01/24/19

Most Recent Stories

More News
Baculoviral IAP Repeat Containing Protein 5 Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis with Regional Analysis to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Baculoviral IAP Repeat Containing Protein 5 Market. The report provides a comprehensive analysis...

IMV.TO : 5.53 (-0.90%)
STML : 6.76 (-2.45%)
Baculoviral IAP Repeat Containing Protein 5 Market 2019 Global Industry Demand, Recent Trends, Size and Share Estimation by 2027 with Top Players

IMV.TO : 5.53 (-0.90%)
STML : 6.76 (-2.45%)
Look for Shares of Stemline Therape to Potentially Rebound after Yesterday's 33.73% Sell Off

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $6.02 to a high of $7.26. Yesterday, the shares fell 33.7%, which took the trading range below the 3-day low of $8.53...

STML : 6.76 (-2.45%)
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS(R) (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net...

STML : 6.76 (-2.45%)
Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that management...

JPM : 133.15 (-2.48%)
STML : 6.76 (-2.45%)
Look for Shares of Stemline Therape to Potentially Pullback after Yesterday's 1.49% Rise

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $10.88 to a high of $11.34. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

STML : 6.76 (-2.45%)
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented data from ELZONRIS (tagraxofusp)...

STML : 6.76 (-2.45%)
Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment...

GSK : 47.23 (-1.23%)
STML : 6.76 (-2.45%)
Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS...

STML : 6.76 (-2.45%)
Watch for Stemline Therape to Potentially Rebound After Falling 3.27% Yesterday

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $9.82 to a high of $10.20. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $10.08...

STML : 6.76 (-2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade STML with:

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

2nd Resistance Point 7.31
1st Resistance Point 7.03
Last Price 6.76
1st Support Level 6.60
2nd Support Level 6.45

See More

52-Week High 18.22
Fibonacci 61.8% 13.56
Fibonacci 50% 12.11
Fibonacci 38.2% 10.67
Last Price 6.76
52-Week Low 6.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar